Clinical Trials Logo

Crohn Disease in Remission clinical trials

View clinical trials related to Crohn Disease in Remission.

Filter by:
  • None
  • Page 1

NCT ID: NCT05463900 Active, not recruiting - Ulcerative Colitis Clinical Trials

Microbial and Human Determinants of the Onset of IBD Flares

Start date: August 1, 2022
Phase:
Study type: Observational

This is a longitudinal, observational study that aims to identify the microbial and human molecular triggers of IBD flares via stool, saliva, and blood metatranscriptomes, whole blood proteome, and collected clinical metadata. This study is direct to participant and will not utilize clinical sites.

NCT ID: NCT05214430 Completed - Clinical trials for Crohn Disease in Remission

Exclusive Enteral Nutrition for Remissionof Crohn's Diseases After Surgery

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

For patients with Crohn's diseases undergoing surgery,whether postoperative exclusive enteral nutrition(EEN) could delay the endoscopic relapse needs exploration.The trial will investigate the efficacy of postoperative EEN for maintaining disease remission.

NCT ID: NCT04321863 Recruiting - Clinical trials for Crohn Disease in Remission

Stratifying Crohn's Using Biomarker Assessment

SCUBA
Start date: August 13, 2020
Phase:
Study type: Observational

Crohn's disease (CD) is a relapsing-remitting condition that requires lifelong monitoring. Non-invasive tests such as faecal calprotectin (FC) are more acceptable to patients and cost-effective than invasive tests such as colonoscopy. FC levels can also accurately predict the degree of healing seen within the bowel at colonoscopy. FC testing is labour intensive, and results are often indeterminate. There is interest in a newer test called quantitative Faecal Immunochemical Testing (qFIT) in patients with CD. qFIT measures the amount of blood within the stool and is used in the Scottish Bowel Cancer Screening Programme. qFIT is an easier and more acceptable test for patients and is less labour intensive and cheaper for the lab to process than FC. qFIT is a useful test to 'rule-out' significant colorectal pathology including bowel cancer, high risk polyps and inflammatory bowel disease in patients in the primary care setting. It has also been used to predict the degree of healing seen within the bowel at colonoscopy and to predict the risk of relapse in patients with UC, but not in CD. There are no studies in the UK to date comparing FIT to FC as a monitoring test in patients with well-controlled CD. Unpublished audit data from our group has suggested that low serum zinc has higher predictive accuracy at determining risk of future flare than both FC and CRP; we are unsure if this is due to higher faecal losses in 'grumbling' CD patients. This study could identify a cheaper, more acceptable and easier to interpret test to guide disease activity monitoring, flare risk and treatment decisions in quiescent CD.

NCT ID: NCT04100005 Recruiting - Crohn Disease Clinical Trials

A Pilot Study to Explore the Role of Gut Flora in Crohn's Disease

Start date: March 2, 2020
Phase:
Study type: Observational [Patient Registry]

This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Crohn's disease.

NCT ID: NCT03172377 Active, not recruiting - Crohn Disease Clinical Trials

Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients

LADI
Start date: May 3, 2017
Phase: Phase 4
Study type: Interventional

Crohn's disease is a chronic inflammatory bowel disease. This disease can be treated with, among other things, biologicals such as adalimumab. Patients use adalimumab for a long time to maintain remission and to prevent relapse of the bowel inflammation. The disadvantages of this therapy are the high price and side effects (such as the higher risk of infection). Currently, adalimumab is given every 2 weeks, by injection under the skin. The optimal time between two injections has never been investigated before. Prior research in patients with rheumatoid arthritis shows that disease remission can be maintained with longer injection-intervals. Our hypothesis is that this is the same for Crohn's disease patients. Our aim is to show non-inferiority of extending the adalimumab dosing interval, under strict disease monitoring in Crohn's disease patients in sustained (>9 months) clinical remission, compared to standard care. During the trial,174 patients with stable Crohn's disease will be divided into 2 groups. One group continues adalimumab injections with the same 2-week interval. And the other group will incrementally extend the interval to 4 weeks, under strict disease monitoring. If a step-down leads to recurrence of disease activity patients will return to the preceding effective dosing interval. Thus, we will investigate whether, and for whom, it is safe to extend the adalimumab injection interval.